- Trials with a EudraCT protocol (9)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
9 result(s) found for: Oocyte abnormalities.
Displaying page 1 of 1.
EudraCT Number: 2022-000753-80 | Sponsor Protocol Number: 000298 | Start Date*: 2022-08-04 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: A randomised, assessor-blind, active-controlled, parallel-group, dose-finding trial to investigate the efficacy and safety of FE 999302 for triggering of final follicular maturation in women underg... | |||||||||||||
Medical condition: Infertility | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) CZ (Prematurely Ended) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004684-58 | Sponsor Protocol Number: FE 200486 CS24 | Start Date*: 2007-01-08 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: A randomised, assessor-blind, parallel groups, multi-centre, exploratory study assessing the impact of subcutaneous administration of degarelix 2.5 mg on synchronisation of follicle cohort compared... | |||||||||||||
Medical condition: Prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020559-29 | Sponsor Protocol Number: IVF-03-01-052 | Start Date*: 2010-09-23 | ||||||||||||||||
Sponsor Name:Pantec Biosolutions AG | ||||||||||||||||||
Full Title: Proof of concept study to investigate the efficacy, safety and tolerability as well as the pharmacokinetics and pharmacodynamics of a newly developed patch containing follicle-stimulating hormone a... | ||||||||||||||||||
Medical condition: Healthy female oocyte donors of normal body weight (body mass index within 18 to 29 kg/m2), age from 20 to 30 years (inclusive), ultrasound of ovaries, normal endocrine status, non-smoker | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: CZ (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002783-40 | Sponsor Protocol Number: 000304 | Start Date*: 2019-07-04 | |||||||||||||||||||||||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||||||||||||||||||||||
Full Title: A randomised, controlled, open label, parallel group, multicentre trial comparing the efficacy and safety of individualised FE 999049 (follitropin delta) dosing, using a long GnRH agonist protocol ... | |||||||||||||||||||||||||||||||||
Medical condition: Infertility in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||||||||||||
Trial protocol: AT (Completed) DK (Completed) NO (Completed) NL (Completed) IT (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-017674-20 | Sponsor Protocol Number: XM17-05 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:BioGeneriX AG | |||||||||||||
Full Title: Efficacy, safety and tolerability of XM17 compared to Gonal-f® in women undergoing assisted reproductive technologies. A multi-national, multi-centre, randomised, controlled, assessor-blind, parall... | |||||||||||||
Medical condition: infertile but ovulatory women undergoing superovulation for assisted reproduction technologies | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) PL (Completed) CZ (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001105-81 | Sponsor Protocol Number: ACT-CYC-300-2013-01 | Start Date*: 2013-07-31 |
Sponsor Name:Actavis Group PTC ehf. | ||
Full Title: Randomized Clinical Trial to Compare the Pregnancy Rates of Vaginally Applied Cyclogest® Pessary and Crinone® 8% Gel After In-vitro Fertilization | ||
Medical condition: Luteal phase support after IVF | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: HU (Completed) BE (Completed) BG (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-004491-17 | Sponsor Protocol Number: REMODEL | Start Date*: 2021-03-31 |
Sponsor Name:UZ Brussel | ||
Full Title: Dydrogesterone versus micronized vaginal progesterone (MVP) for luteal phase support (LPS) in hormone replacement therapy (HRT) frozen embryo transfer (FET) cycles. | ||
Medical condition: progesterone as luteal phase supplementation in frozen embryo transfer cycles | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004554-30 | Sponsor Protocol Number: LOXO-BTK-20020 | Start Date*: 2021-06-04 | |||||||||||
Sponsor Name:Loxo Oncology Inc | |||||||||||||
Full Title: A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/... | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) HR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000043-49 | Sponsor Protocol Number: LOXO-BTK-20022 | Start Date*: 2021-08-16 | |||||||||||
Sponsor Name:Loxo Oncology Inc | |||||||||||||
Full Title: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Sm... | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) PL (Trial now transitioned) NO (Completed) HU (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
